Viva Biotech Holdings (Viva Biotech) filed a Next Day Disclosure Return showing that 3.50 million ordinary shares were repurchased on 25 June 2026 through on-market transactions on the Hong Kong Stock Exchange. The shares were acquired within a price range of HKD 1.04–1.10, with a volume-weighted average cost of HKD 1.06 per share, bringing the aggregate consideration for the day to HKD 3.72 million.

Including the latest transaction, shares repurchased between 8 and 25 June 2026 but not yet cancelled total 9.49 million, equivalent to approximately 0.45% of the company’s 2.10 billion issued shares. All repurchased shares are earmarked for cancellation; no treasury shares are being held.

The buybacks are executed under the share repurchase mandate approved on 12 June 2025, which authorises Viva Biotech to repurchase up to 212.84 million shares. As of 25 June 2026, cumulative purchases under this mandate amount to 34.80 million shares, representing 1.64% of the issued share capital on the date the mandate was granted.

Under Hong Kong Listing Rule 10.06(3)(a), the company is subject to a moratorium on new share issues or treasury-share sales until 25 July 2026 following the latest on-market repurchase.